{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-26-000006","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2026-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.809506+00:00","generated_at":"2026-05-16T06:55:45.392318+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Altimmune raises ~$75M in registered direct offering of common stock and pre-funded warrants","bullets":["Issued 12.4M shares and pre-funded warrants for 4.6M shares at $4.40/share; gross proceeds ~$75M.","Closing expected Jan 29, 2026; Titan Partners acted as sole placement agent.","Pre-funded warrants exercisable at $0.001, no expiration, 9.99% beneficial ownership limit.","Directors and officers subject to 30-day lock-up agreements with customary exceptions."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-26-000006","json":"https://secwatch.observer/filing/0001326190-26-000006.json","markdown":"https://secwatch.observer/filing/0001326190-26-000006.md","text":"https://secwatch.observer/filing/0001326190-26-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000006/0001326190-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000006/alt-20260127x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:55:45.392318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"173c238da03261093087922be73bcb67bf2add10","claim":"Altimmune, Inc. entered into Placement Agency Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (effective 2026-01-27).","evidence_excerpt":"The Company also entered into a Placement Agency Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (“Titan Partners”) (the “Placement Agency Agreement,” and together with the Securities Purchase Agreement, the “Agreements”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000006/0001326190-26-000006-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Titan Partners Group LLC, a division of American Capital Partners, LLC"},{"label":"Effective","value":"2026-01-27"}],"fact_type":"material_agreement"},{"claim_id":"97b33d92df92671e26ac41c60758ad2b482a4e86","claim":"Altimmune, Inc. entered into Securities Purchase Agreement with a new fundamental institutional investor valued at approximately $75 million (effective 2026-01-27).","evidence_excerpt":"On January 27, 2026, Altimmune, Inc. (the “Company”) entered into a Securities Purchase Agreement with a new fundamental institutional investor (the “Securities Purchase Agreement”) relating to the issuance of 12,397,920 shares of the Company’s common stock, par value of $0.0001 per share (the “Common Stock”) and pre-funded warrants (the “Pre-Funded Warrants”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000006/0001326190-26-000006-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a new fundamental institutional investor"},{"label":"Value","value":"approximately $75 million"},{"label":"Effective","value":"2026-01-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}